Large scale production of pharmaceuticals follows the convention of growing material in an environment typically hosted by E. coli bacteria. From insulin to vaccines to modern drugs, this laborious, time-consuming and inefficient process is the reason behind the extreme costs and long delays. Not to mention the voluminous and sometimes toxic waste stream produced with each batch. The science of NTx is changing all this. For good.
Our proprietary NTxpress™ in vitro protein biosynthesis platform and NTxscribe™ in vitro RNA biosynthesis platform, enable us to produce definitive quantities of biologics that are unrivaled in purity, stability, production turnaround and cost. This novel cell-free biosynthesis technology accelerates the production of drug leads while offering advanced real-time controls, short turnaround times, material selectivity, sustainability and scalability.
Nature’s Toolbox Drug Identification software (DruID™) identifies potential new drug leads from nature’s inventory. We are plotting biosynthetic pathways using a fully in situ/in vitro approach . Our goal is to generate a novel drug discovery pipeline of biologically relevant drug leads with a high probability for efficacy and safety.
Leveraging our proprietary cell-free technology, NTxpress™ is the world’s first fully recombinant cell-free system based on thermophile strains and using continuous flow bioreactors. Significantly outperforming current pharmaceutical fermentation processes, NTxpress™ provides rapid access to new active compounds and has been proven to reduce turn-around times by a factor of 150.
NTx works towards positively influencing and securing the world vaccine supply by developing rapid on-demand production of the full spectrum of protein vaccines. From common childhood vaccines, to high-demand, emergency and experimental vaccines, NTx is capable of accelerated prototyping and manufacturing, with increased purity and greater stability while reducing both cost and production time.
Redesigning Vaccine Production for Good
Providing cheaper common childhood and WHO recommended vaccines
Accelerating response time for high demand and medical emergency vaccines
Design and development of mosaic and multivalent vaccines
Supporting the development of experimental vaccines